Pancreatic Stone Protein Testing Market Trends

  • Report ID: 4566
  • Published Date: Feb 15, 2023
  • Report Format: PDF, PPT

Pancreatic Stone Protein Testing Market Trends

Growth Drivers

  • Growing Prevalence of Diabetes Globally with Changing food habits

  • The World Health Organization states that 422 million people worldwide are diabetic; each year, about 1.5 million people die of diabetes.
  • The rising need for pancreatic stone protein testing in diabetic patients, particularly in Type 3c, also known as pancreatogenic diabetes is expected to drive the market growth during the forecast period. It is estimated that there are more people with type 3c diabetes than type 1 diabetes, and patients with pancreatitis diseases have about a 27 to 79% chance of developing type 3c diabetes, which is further estimated to promote the adoption of pancreatic stone protein testing for diabetic patients.
  • Increasing Geriatric Population Around the World which Reduces Immunity According to the World Health Organization, the number of people aged over 60 years was 1 billion in 2019 and is expected to increase to 2.1 billion by 2050. 

  • Change in Lifestyle, Increasing Consumption of Alcohol Among People – As per WHO, alcohol is a cause of more than 200 serious medical conditions. Worldwide, 3 million deaths are attributed to excessive alcohol consumption every year, which is 5.3 percent of all deaths.

  • Increasing Cases of Pancreatic Cancer with Lack of Early Diagnosis – Pancreatic stone protein testing also acts as cancer biomarkers, thus the surge in the number of pancreatic cancer cases is further expected to drive the market’s growth. As of 2022, nearly 62,000 people were diagnosed with pancreatic cancer and approximately 49,500 of them died in a similar year in the United States.
  • Globally Increasing Health Care Expenditure to Improve the Health of People - In 2019, according to data provided by the World Bank, global health expenditures had grown from 9.7% of the world's GDP in 2018 to 9.83% in 2019.


  • Higher Cost of Pancreatic Stone Protein (PSP) Testing
  • Highly Sensitive Testing Devices 
  • Accuracy Issues with PSP Biomarkers 

The PSP test may give false or misdiagnosed results as some of the symptoms of the disease are similar to Parkinson’s disease, Alzheimer’s disease, and neurodegenerative disorders. Sometimes the memory issues and change in behavior are misdiagnosed as symptoms of depression or dementia instead of PSP by the physicians. Hence, these factors of misdiagnosis are projected to limit the market growth in the coming years.

Pancreatic Stone Protein Market: Key Insights

Base Year


Forecast Year




Base Year Market Size (2022)

~ USD 4 Billion

Forecast Year Market Size (2033)

~ USD 5 Billion

Regional Scope

  • North America (U.S., and Canada)
  • Latin America (Mexico, Argentina, Rest of Latin America)
  • Asia-Pacific (Japan, China, India, Indonesia, Malaysia, Australia, Rest of Asia-Pacific)
  • Europe (U.K., Germany, France, Italy, Spain, Russia, NORDIC, Rest of Europe)
  • Middle East and Africa (Israel, GCC North Africa, South Africa, Rest of the Middle East and Africa)
Get more information on this report: Request Free Sample PDF

Browse Key Market Insights with Data Illustration:

Author Credits:  Radhika Pawar

  • Report ID: 4566
  • Published Date: Feb 15, 2023
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

Increasing prevalence of diabetes globally along with rising demand for pancreatic stone protein testing as a biomarker are some of the major factors anticipated to drive the growth of the market.

The market is anticipated to attain a CAGR of 3% over the forecast period, i.e., 2023-2033.

High price associated with pancreatic stone protein testing and inaccuracy with PSP biomarkers are some of the factors estimated to hamper market growth.

The market in North America is projected to hold the largest market share by the end of 2033 and provide more business opportunities in the future.

The major players in the market are RayBiotech Life, Inc., CUSABIO TECHNOLOGY LLC, LifeSpan BioSciences, Inc, Abbexa Limited, Boster Biological Technology CO LTD, Aviva Systems Biology Corporation, Glenmed Professional Healthcare Solutions., CREATIVE DIAGNOSTICS, Inc, Biomol GmbH, and others.

The company profiles are selected based on the revenues generated from the product segment, geographical presence of the company which determine the revenue generating capacity as well as the new products being launched into the market by the company.

The market is segmented by technique, disease type, age group, end user, and by region.

The sepsis disease segment is anticipated to garner the largest market size by the end of 2033 and display significant growth opportunities.
Inquiry Before Buying Request Free Sample

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying